References
Hannaway CD, Hull TL (2008) Current considerations in the management of rectovaginal fistula from Crohn’s disease. Colorectal Dis 10:747–755 (discussion 755)
Bonovas S, Fiorino G, Allocca M et al (2016) Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 14:1385-1397.e10
El-Gazzaz G, Hull T, Mignanelli E et al (2010) Analysis of function and predictors of failure in women undergoing repair of Crohn’s related rectovaginal fistula. J Gastrointest Surg 14:824–829
Lightner AL, Dozois EJ, Dietz AB, Fletcher JG, Friton J, Butler G, Faubion WA (2020) Matrix-delivered autologous mesenchymal stem cell therapy for refractory rectovaginal Crohn’s fistulas. Inflamm Bowel Dis 26(5):670–677. https://doi.org/10.1093/ibd/izz215 (PMID: 31605115)
Funding
Crohn’s and Colitis Foundation of America.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval statement
IRB 20-936 approval from Cleveland Clinic.
Conflict of interest
A.L consultant for Takeda, Ossium, Mesoblast, Boomerang.
Proof of consent
Consent was obtained for photo and video of the patient herein. No portion of this video has been presented elsewhere.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary file1 (MP4 147519 KB)
Rights and permissions
About this article
Cite this article
Otero-Piñeiro, A.M., Lightner, A.L. Adult allogenic bone marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn’s disease. Tech Coloproctol 26, 831–832 (2022). https://doi.org/10.1007/s10151-022-02667-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10151-022-02667-0